Tuberculosis complicating treatment of hepatitis C in an HIV-infected haemophilia A patient

Haemophilia. 2006 Sep;12(5):545-7. doi: 10.1111/j.1365-2516.2006.01289.x.

Abstract

Pegylated interferon (pegIFN)/ribavirin has been established as the treatment of choice for chronic hepatitis C in HIV co-infected individuals [1-3]. We report the case of an individual who was well prior to treatment, but was diagnosed with tuberculous adenitis after receiving 12 weeks of pegIFN/ribavirin therapy. The association of pegIFN and ribavirin therapy with tuberculosis (TB) has not been described previously.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Antiviral Agents / adverse effects
  • HIV Infections / complications*
  • Hemophilia A / complications*
  • Hepatitis C, Chronic / complications
  • Hepatitis C, Chronic / drug therapy*
  • Humans
  • Interferon alpha-2
  • Interferon-alpha / adverse effects
  • Lymphadenitis / chemically induced*
  • Male
  • Polyethylene Glycols / adverse effects
  • Recombinant Proteins
  • Ribavirin / adverse effects
  • Treatment Outcome
  • Tuberculosis, Lymph Node / chemically induced*

Substances

  • Antiviral Agents
  • Interferon alpha-2
  • Interferon-alpha
  • Recombinant Proteins
  • Polyethylene Glycols
  • Ribavirin
  • peginterferon alfa-2a